

Haynes Boone Advises on Acquisition of Volumetric Biotechnologies

November 1, 2021

PRACTICES Precision Medicine and Digital Health

Haynes Boone advised firm client Volumetric Biotechnologies in its sale to 3D Systems (NYSE:DDD) to help advance research in life science technology and 3D printing for regenerative medicine.

Moreover, a Haynes Boone patent procurement team featuring members of the firm's Precision Medicine and Digital Health Practice helped Volumetric build out an extensive IP portfolio that was a core asset of the transaction.

The acquisition is structured as a \$45 million closing payment, with up to \$355 million additional opportunity linked to the attainment of significant steps in the demonstration of human applications through Dec. 31, 2035. These payments comprise approximately half cash and half stock. If all milestones are accomplished, the total purchase price for the acquisition is \$400 million. The transaction is expected to close in the fourth quarter, according to a 3D Systems press release.

Volumetric is a Houston-based biotech company working to manufacture human organs using bioprinting methods. Its team of bioengineers and scientists has focused primarily on the human liver and the underlying technologies required to create these highly complex biological structures.

3D Systems is a manufacturing solutions partner that addresses a variety of advanced applications in healthcare and industrial markets, such as medical and dental, aerospace & defense, automotive, and durable goods. With the acquisition of Volumetric, 3D Systems plans to establish a world-class research capability in Houston, Texas, a region committed to leadership in technologies related to life sciences.

Alan Bickerstaff, partner at Shearman and Sterling, LLP led the transaction deal team for Volumetric Biotechnologies. Hunton Andrews Kurth, LLP served as legal advisor to 3D Systems on the transaction.

Haynes Boone's Precision Medicine and Digital Health Practice Group provides full-service counsel to the key players in precision medicine and digital health – from technology startups to established corporations, health insurers, pharmaceuticals, and investors supporting the industry. The team draws on the firm's highly regarded healthcare, life sciences, technology and IP experience to address trends in evolving markets, cutting-edge advances in technology, and legal and regulatory changes.

Haynes Boone is an international corporate law firm with offices in Texas, New York, California, Charlotte, Chicago, Denver, Washington, D.C., London, Mexico City, and Shanghai, providing a full spectrum of legal services in energy, technology, financial services, and private equity. With 600 lawyers, Haynes Boone is ranked among the largest U.S.-based firms by *The National Law Journal*, *The American Lawyer* and *The Lawyer*. It was recognized for excellence in the BTI Consulting

Group's 2021 "A-Team" report, which identifies the law firms that in-house counsel commend for providing superior client service.